These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15880067)

  • 1. Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation.
    Gruessner RW; Kandaswamy R; Humar A; Gruessner AC; Sutherland DE
    Transplantation; 2005 May; 79(9):1184-9. PubMed ID: 15880067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.
    Uemura T; Ramprasad V; Matsushima K; Shike H; Valania T; Kwon O; Ghahramani N; Shah R; Farooq U; Khan A; Kadry Z
    Transplantation; 2011 Sep; 92(6):678-85. PubMed ID: 21841541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA
    Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation.
    Freise CE; Kang SM; Feng S; Posselt A; Hirose K; Hirose R; Stock P
    Transplant Proc; 2004 May; 36(4):1067-8. PubMed ID: 15194370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
    Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ
    Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
    Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
    Muthusamy AS; Vaidya AC; Sinha S; Roy D; Elker DE; Friend PJ
    Am J Transplant; 2008 Oct; 8(10):2126-31. PubMed ID: 18828772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F; Stock P
    Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation.
    Pascual J; Pirsch JD; Odorico JS; Torrealba JR; Djamali A; Becker YT; Voss B; Leverson GE; Knechtle SJ; Sollinger HW; Samaniego-Picota MD
    Transplantation; 2009 Jan; 87(1):125-32. PubMed ID: 19136902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
    Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
    Sampaio MS; Chopra B; Sureshkumar KK
    Transplantation; 2017 Oct; 101(10):2527-2535. PubMed ID: 28475563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.
    Thai NL; Khan A; Tom K; Blisard D; Basu A; Tan HP; Marcos A; Fung JJ; Starzl TE; Shapiro R
    Transplantation; 2006 Dec; 82(12):1621-4. PubMed ID: 17198247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.